Anavex Life Sciences
NY · 4 filings, 2025
Lobbying spend · 2025
$240K
to shape legislation
About the organization
ANAVEX 3-71, also known as AF710B, is a muscarinic acetylcholine M1 receptor positive allosteric modulator and sigma σ1 receptor agonist which is under development for the treatment of schizophrenia, Alzheimer's disease, frontotemporal dementia, other neurodegenerative disorders, and Parkinson's disease. It is taken orally. via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues
2Through these firms · 1
FORBES-TATE
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews